asa glp 1 agonists GLP-1 medications safe to continue before surgery in patients with diabetes and obesity 2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations

Paradoxically, this increase has been associated with improved all-cause mortality as well as cardiovascular mortality, according to a post hoc analysis of the PROactive trial (259)

Delayed gastric emptying was the most common problem (80% of patients), while 33% had slower small bowel and colon transit [29]

In addition, the follow-up duration of ELIXA was also relatively short (2.1 years), especially when compared with the follow-up duration of 5.4 years in the REWIND trial [60, 62]

Huang, G., Zhang, Y., Zhang, Y

USA 110 , 52115216 (2013)

With GLP-1 receptor agonists in the mix, glucagon secretion takes a back seat, leading to a decrease in glucose production in the liver